共 113 条
Salmon calcitonin: a review of current and future therapeutic indications
被引:159
作者:
Chesnut, C. H., III
[1
]
Azria, M.
[2
]
Silverman, S.
[3
]
Engelhardt, M.
[2
]
Olson, M.
[2
]
Mindeholm, L.
[2
]
机构:
[1] Univ Washington, Osteoporosis Res Grp, Seattle, WA 98195 USA
[2] Novartis Pharma AG, Basel, Switzerland
[3] Cedars Sinai Med Ctr, Dept Med & Rheumatol, Los Angeles, CA 90048 USA
关键词:
D O I:
10.1007/s00198-007-0490-1
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Salmon calcitonin, available as a therapeutic agent for more than 30 years, demonstrates clinical utility in the treatment of such metabolic bone diseases as osteoporosis and Paget's disease, and potentially in the treatment of osteoarthritis. This review considers the physiology and pharmacology of salmon calcitonin, the evidence based research demonstrating efficacy and safety of this medication in postmenopausal osteoporosis with potentially an effect on bone quality to explain its abilities to reduce the risk of spine fracture, the development of an oral salmon calcitonin preparation, and the therapeutic rationale for this preparation's chondroprotective effect in osteoarthritis.
引用
收藏
页码:479 / 491
页数:13
相关论文